Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Sri Sahasranaman, Ph.D.

Key Takeaway: Sri Sahasranaman has been appointed as Senior Vice President of Clinical Pharmacology at Prelude Therapeutics. He brings over 20 years of experience in drug development, having previously built the Global Clinical Pharmacology organization at BeiGene. His extensive background includes leadership roles at Genentech, Novartis, and Sanofi, with a focus on oncology and innovative dose optimization.
Price reaction · baseline $1.72 (2025-11-03T18:44:00.000Z) · hit during market hours · 2 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+131.4%
day 1
+2.3%
day 3
-21.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sri Sahasranaman has over 20 years of drug development experience.
  • He has successfully led clinical pharmacology for multiple NDA/BLA filings.
  • His expertise spans various therapeutic areas, enhancing Prelude's capabilities.
  • He has a strong academic background with degrees from reputable institutions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Sri Sahasranaman is Senior Vice President of Clinical Pharmacology at Prelude Therapeutics and is responsible for leading and overseeing clinical pharmacology and pharmacometrics strategies to facilitate clinical development of assets. Before joining Prelude, Sri built and scaled up the Global Clinical Pharmacology organization at BeiGene (now BeOne) for six years. Previously, Sri worked at Genentech, Novartis and Sanofi and has over 20 years of drug development experience in multiple therapeutic areas including oncology, neuroscience and respiratory. He has provided clinical pharmacology leadership for four NDA/BLA and multiple sNDA/sBLA filings in his career. Sri received his B. Pharm (Hons.) degree from BITS Pilani, India, M.S. in Pharmacy from the National University of Singapore and Ph.D. in Pharmaceutical Sciences from the University of Florida. His areas of professional and research interest include innovative dose optimization approaches in oncology, leveraging global clinical data to bridge efficacy and safety across regions, formulation bridging and pediatric drug development in oncology.

Frequently Asked Questions

What is Sri Sahasranaman's role at Prelude Therapeutics?

Sri Sahasranaman is the Senior Vice President of Clinical Pharmacology.

What experience does Sri Sahasranaman bring?

He has over 20 years of drug development experience in various therapeutic areas.

Where did Sri work before Prelude Therapeutics?

He previously worked at BeiGene, Genentech, Novartis, and Sanofi.

What are Sri's academic qualifications?

He holds a B. Pharm, an M.S. in Pharmacy, and a Ph.D. in Pharmaceutical Sciences.

Last updated: Nov 3, 2025